Comparison Between 10- and 14-Day Hybrid Regimens for Helicobacter pylori Eradication: A Randomized Clinical Trial

Helicobacter

Volumn 20, Issue 4, 2015, Pages 299-304

  Metanat, Hassan Ali ^a   Valizadeh, Seyed Mohammad ^a   Fakheri, Hafez ^a   Maleki, Iradj ^a   Taghvaei, Tarang ^a   Hosseini, Vahid ^a   Bari, Zohreh ^a  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Eradication; Helicobacter pylori; Hybrid

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; PANTOPRAZOLE; TINIDAZOLE; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTIINFECTIVE AGENT;

ABDOMINAL PAIN; ADULT; ANXIETY DISORDER; ARTICLE; COMPARATIVE EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG SAFETY; EPIGASTRIC PAIN; ERADICATION THERAPY; FEMALE; FLATULENCE; HAIRY TONGUE; HEADACHE; HELICOBACTER INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALAISE; MALE; METALLIC TASTE; NAUSEA AND VOMITING; PEPTIC ULCER; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UREA BREATH TEST; COMBINATION DRUG THERAPY; DRUG EFFECTS; DUODENITIS; GASTRITIS; GROWTH, DEVELOPMENT AND AGING; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; IRAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE;

HELICOBACTER PYLORI;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AMOXICILLIN; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; DUODENITIS; FEMALE; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IRAN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PEPTIC ULCER; TINIDAZOLE;

EID: 84937525941     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/hel.12202     Document Type: Article

References (25)

1. Malfertheiner P, Selgrad M, Bornschein J. Helicobacter pylori: clinical management. Curr Opin Gastroenterol 2012;28:608-14.
2. Shmuely H, Katicic M, Filipec Kanizaj T, Niv Y. Helicobacter pylori and nonmalignant diseases. Helicobacter 2012;17(Suppl 1):22-5.
3. O'Connor A, Molina-Infante J, Gisbert JP, O'Morain C. Treatment of Helicobacter pylori infection 2013. Helicobacter 2013;18(Suppl 1):58-65.
4. Wu JY, Liou JM, Graham DY. Evidence-based recommendations for successful Helicobacter pylori treatment. Expert Rev Gastroenterol Hepatol 2014;8:21-8.
5. Zullo A, De Francesco V, Hassan C, et al. Modified sequential therapy regimens for Helicobacter pylori eradication: a systematic review. Dig Liver Dis 2013;45:18-22.
6. Zullo A, Hassan C, Ridola L, De Francesco V, Vaira D. Standard triple and sequential therapies for Helicobacter pylori eradication: an update. Eur J Intern Med 2013;24:16-9.
7. Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ 2013;347:f4587.
8. Georgopoulos S, Papastergiou V, Xirouchakis E, et al. Nonbismuth quadruple "concomitant" therapy versus standard triple therapy, both of the duration of 10 days, for first-line H. pylori eradication: a randomized trial. J Clin Gastroenterol 2013;47:228-32.
9. Kim SY, Lee SW, Hyun JJ, et al. Comparative study of Helicobacter pylori eradication rates with 5-day quadruple "concomitant" therapy and 7-day standard triple therapy. J Clin Gastroenterol 2013;47:21-4.
10. Kongchayanun C, Vilaichone RK, Pornthisarn B, Amornsawadwattana S, Mahachai V. Pilot studies to identify the optimum duration of concomitant Helicobacter pylori eradication therapy in Thailand. Helicobacter 2012;17:282-5.
11. Yanai A, Sakamoto K, Akanuma M, Ogura K, Maeda S. Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication: a randomized study in Japan. World J Gastrointest Pharmacol Ther 2012;3:1-6.
12. Wu JY, Hsu PI, Wu DC, Graham DY, Wang WM. Feasibility of shortening 14-day hybrid therapy while maintaining an excellent Helicobacter pylori eradication rate. Helicobacter 2014;19:207-13.
13. Hsu PI, Wu DC, Wu JY, Graham DY. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter 2011;16:139-45.
14. Oh DH, Lee DH, Kang KK, et al. The efficacy of hybrid therapy as first-line regimen for Helicobacter pylori infection compared with sequential therapy. J Gastroenterol Hepatol 2014;29:1171-6.
15. Zullo A, Scaccianoce G, De Francesco V, et al. Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study. Clin Res Hepatol Gastroenterol 2013;37:647-50.
16. De Francesco V, Hassan C, Ridola L, Giorgio F, Ierardi E, Zullo A. Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication: a prospective randomized study. J Med Microbiol 2014;63:748-52.
17. Molina-Infante J, Romano M, Fernandez-Bermejo M, et al. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology 2013;145:121-8 e1.
18. Sardarian H, Fakheri H, Hosseini V, Taghvaei T, Maleki I, Mokhtare M. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial. Helicobacter 2013;18:129-34.
19. Kanizaj TF, Kunac N. Helicobacter pylori: future perspectives in therapy reflecting three decades of experience. World J Gastroenterol 2014;20:699-705.
20. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter 2007;12:275-8.
21. Sadeghifard N, Seidnazari T, Ghafourian S, et al. Survey in Iran of clarithromycin resistance in Helicobacter pylori isolates by PCR-RFLP. Southeast Asian J Trop Med Public Health 2013;44:89-95.
22. Talebi Bezmin Abadi A, Mobarez AM, Taghvaei T, Wolfram L. Antibiotic resistance of Helicobacter pylori in Mazandaran, North of Iran. Helicobacter 2010;15:505-9.
23. Shokrzadeh L, Jafari F, Dabiri H, et al. Antibiotic susceptibility profile of Helicobacter pylori isolated from the dyspepsia patients in Tehran, Iran. Saudi J Gastroenterol 2011;17:261-4.
24. Milani M, Ghotaslou R, Akhi MT, et al. The status of antimicrobial resistance of Helicobacter pylori in Eastern Azerbaijan, Iran: comparative study according to demographics. J Infect Chemother 2012;18:848-52.
25. De Francesco V, Giorgio F, Hassan C, et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis 2010;19:409-14.